Stay up-to-date with onychomycosis (tinea unguium) market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. HTF Market Report released a new research document of 68 pages on industry titled as ‘Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018’ with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors such as Almirall SA, Blueberry Therapeutics Ltd, Dermala Inc, Eisai Co Ltd, Helix BioMedix Inc, Hexima Ltd The report will help you gain market insights, future trends and growth prospects for forecast period of 2018 – 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/896022-onychomycosis-5
Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018
The latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.
Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 2 and 2 respectively.
Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Almirall SA, Blueberry Therapeutics Ltd, Dermala Inc, Eisai Co Ltd, Helix BioMedix Inc, Hexima Ltd, Kaken Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Moberg Pharma AB, NAL Pharmaceuticals Ltd, Novabiotics Ltd, Novan Inc, Viamet Pharmaceuticals Inc
Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/896022-onychomycosis-5
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) – Overview
Onychomycosis (Tinea Unguium) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) – Companies Involved in Therapeutics Development
Almirall SA
Blueberry Therapeutics Ltd
Dermala Inc
Eisai Co Ltd
Helix BioMedix Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) – Drug Profiles
BB-0305 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1275 – Drug Profile
Produc
….Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/896022-onychomycosis-5
It’s vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=896022
About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
Your information will never be shared with any third party.